BSH/UKMS good practice paper on Investigation and management of the monoclonal gammopathy of undetermined significance
This Good Practice Paper provides expert recommendations for the diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance (MGUS). It also introduces the recently recognised concept of monoclonal gammopathy of clinical significance (MGCS), outlining how this condition should be managed. The paper discusses the potential role of targeted population screening for MGUS to improve early detection.
MGUS is characterised by a low level of monoclonal protein and absence of organ damage typical of myeloma or related malignancies. It is common in older adults and carries a risk of progression to multiple myeloma or other lymphoplasmacytic malignancies. This paper emphasises best laboratory practices for accurate diagnosis and highlights the importance of risk stratification to guide patient management and monitoring.
Use Case
Type
Sources
You might also like
ASCO living guideline on Treatment of multiple myeloma
ASCO’s living guideline covers treatment across the myeloma pathway. This update focuses on relapsed or refractory myeloma, recommending ciltacabtagene autoleucel and teclistamab plus daratumumab as preferred options at first relapse for eligible patients who have not previously received BCMA-directed treatment.
ASCO GuidelineBSH guideline on Early diagnosis of AL amyloidosis in haematology, cardiology, neurology, renal and general clinics
Read the British Society for Haematology guideline on early diagnosis of AL amyloidosis, including when to suspect it and when urgent haematology review may be needed.
BSH GuidelineBSH good practice paper on Diagnosis and management of monoclonal gammopathy of renal significance
The paper outlines a consensus approach to diagnosis, treatment and monitoring of MGRS, including guidance on the investigations required to confirm the condition, principles of supportive care, and haematological treatment strategies. It also highlights the need for ongoing multidisciplinary collaboration in managing this rare but clinically important disorder.
BSH GuidelineBSH/UKMS good practice paper on Advanced imaging for earlier diagnosis and morbidity prevention in myeloma
This Good Practice Paper from BSH/UKMS provides expert recommendations on the use of advanced imaging techniques, such as whole-body MRI and FDG-PET/CT, in the diagnosis and management of myeloma. It emphasises the importance of early detection of bone marrow disease to prevent complications and improve patient outcomes.
BSH/UKMS good practice paper on Diagnosis and initial treatment of transplant-eligible high-risk myeloma patients
The British Society for Haematology (BSH) and UK Myeloma Society (UKMS) have published a Good Practice Paper offering recommendations on the diagnosis and early treatment of transplant-eligible patients with high-risk myeloma.
BSH guideline on Cancer-associated venous thrombosis in adults (second edition)
Venous thromboembolism (VTE) is a serious complication in myeloma patients, increasing the risk of morbidity and mortality. This updated British Society for Haematology (BSH) guideline provides UK-focused, evidence-based recommendations on the prevention and management of cancer-associated thrombosis (CAT), incorporating the latest research and treatment options available within the NHS.
BSH GuidelineBSH good practice paper on The use of imaging in the management of patients with myeloma
This Good Practice Paper offers evidence-based recommendations on using these imaging methods at diagnosis and during follow-up to improve detection, disease assessment, and treatment decisions in myeloma care.
BSH Guideline
